Non-Compliance at Italian Sterile Manufacturer
Recommendation
16-18 June 2026
Good Engineering Practice for Pharmaceutical Companies and Suppliers
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the course of an inspection conducted in October 2018, the Italian health authority discovered several GMP deviations at an Italian manufacturer. The Italian manufacturer produces aseptically prepared LVPs (Large Volume Parenterals) and powders, as well as terminally sterilised LVPs. During the inspection, deficiencies were found in the areas of sterile products (both aseptically prepared and terminally sterilised), secondary packaging and quality control (microbiological, chemical/physical and biological.
The authority has reported 17 major and one "other" deficiencies. The major deficiencies concerned the qualification of critical equipment (autoclaves, depyrogenation tunnels, lyophilisers, CCI testing equipment for ampoules, visual inspection systems). Besides, it has been observed that data integrity was not assured in the quality control equipment and that - all things considered - there was a weak system in place for the investigation of deviations.
As a result of the inspection i.e. of the deficiencies discovered, the manufacturing authorisation of the company has been suspended.
Source: EMA's EudraGMDP database
Related GMP News
28.04.2026FDA remains active in Europe - further Inspections despite MRAs
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight